Oncosil Medical Ltd (AU:OSL) — Market Cap & Net Worth
Market Cap & Net Worth: Oncosil Medical Ltd (OSL)
Oncosil Medical Ltd (AU:OSL) has a market capitalization of $13.22 Million (AU$18.69 Million) as of September 24, 2026. Listed on the AU stock exchange, this Australia-based company holds position #26441 globally and #1204 in its home market, demonstrating a -4.08% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Oncosil Medical Ltd's stock price AU$0.94 by its total outstanding shares 23615334 (23.62 Million). Also see Oncosil Medical Ltd assets under control for a full breakdown of the balance sheet.
Oncosil Medical Ltd Market Cap History: 2015 to 2026
Oncosil Medical Ltd's market capitalization history from 2015 to 2026. Data shows growth from $3.29 Million to $15.71 Million (20.53% CAGR). Also see OSL cash flow metrics for how efficiently the company converts equity into cash flow.
Oncosil Medical Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Oncosil Medical Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Oncosil Medical Ltd share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
13.84x
Oncosil Medical Ltd's market cap is 13.84 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.13 Million | $3.84 Million | -$4.77 Million | 0.29x | N/A |
| 2017 | $2.04 Million | $3.51 Million | -$7.02 Million | 0.58x | N/A |
| 2018 | $2.43 Million | $4.45 Million | -$8.54 Million | 0.55x | N/A |
| 2019 | $2.24 Million | $3.63 Million | -$8.57 Million | 0.62x | N/A |
| 2020 | $1.61 Million | $2.76 Million | -$4.26 Million | 0.58x | N/A |
| 2021 | $603.21K | $213.07K | -$10.43 Million | 2.83x | N/A |
| 2022 | $611.56K | $231.79K | -$10.73 Million | 2.64x | N/A |
| 2023 | $150.38K | $367.68K | -$11.34 Million | 0.41x | N/A |
| 2024 | $100.26K | $516.63K | -$11.91 Million | 0.19x | N/A |
| 2025 | $16.21 Million | $1.17 Million | -$15.10 Million | 13.84x | N/A |
Competitor Companies of OSL by Market Capitalization
Companies near Oncosil Medical Ltd in the global market cap rankings as of September 24, 2026. Review Oncosil Medical Ltd (OSL) tangible equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Oncosil Medical Ltd by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #122 globally with a market cap of $180.30 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #228 globally with a market cap of $109.30 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #237 globally with a market cap of $105.52 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #240 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #122 | Abbott Laboratories | NYSE:ABT | $180.30 Billion | $103.69 |
| #228 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $90.77 |
| #237 | Stryker Corporation | NYSE:SYK | $105.52 Billion | $275.09 |
| #240 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Oncosil Medical Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Oncosil Medical Ltd's market cap moved from $3.29 Million to $ 15.71 Million, with a yearly change of 20.53%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$15.71 Million | -3.09% |
| 2025 | AU$16.21 Million | +16066.67% |
| 2024 | AU$100.26K | -33.33% |
| 2023 | AU$150.38K | -75.41% |
| 2022 | AU$611.56K | +1.39% |
| 2021 | AU$603.21K | -62.51% |
| 2020 | AU$1.61 Million | -28.03% |
| 2019 | AU$2.24 Million | -8.10% |
| 2018 | AU$2.43 Million | +19.34% |
| 2017 | AU$2.04 Million | +80.21% |
| 2016 | AU$1.13 Million | -65.58% |
| 2015 | AU$3.29 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 23rd, 2026 the market cap of Oncosil Medical Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $13.22 Million USD |
| MoneyControl | $13.22 Million USD |
| MarketWatch | $13.22 Million USD |
| marketcap.company | $13.22 Million USD |
| Reuters | $13.22 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Oncosil Medical Ltd
OncoSil Medical Limited, a medical device company, develops and commercializes localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The company's lead product is OncoSil, a single-use brachytherapy device for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorp… Read more